Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	87.62	148.64	57.24	175.69	45.01	24.76
Short-Term Investments	566.39	489.44	534.85	376.09	131.99	116.6
Cash & Short-Term Investments	654.02	638.08	592.09	551.77	177	141.36
Cash Growth	24.18%	7.77%	7.31%	211.74%	25.21%	18.48%
Accounts Receivable	-	0.87	0.99	2.77	1.82	0.81
Other Receivables	0.94	-	-	-	-	-
Receivables	0.94	0.87	0.99	2.77	1.82	0.81
Prepaid Expenses	4.69	6.01	7.23	4.48	2.96	2.7
Total Current Assets	659.64	644.96	600.3	559.02	181.78	144.87
Property, Plant & Equipment	18.42	18.85	16.91	12.52	6.88	2.59
Long-Term Investments	149.32	292.79	128.68	-	-	-
Long-Term Deferred Tax Assets	1.05	0.8	0.51	0.47	0.52	0.24
Other Long-Term Assets	7.47	7.4	7.75	-	-	-
Total Assets	835.9	964.8	754.15	572.01	189.19	147.7
Accounts Payable	5.43	8.6	8.49	3.82	3.04	2.47
Accrued Expenses	21.8	17.03	13.38	9.78	7.76	6.15
Current Portion of Long-Term Debt	-	-	-	-	-	4.65
Current Portion of Leases	1.39	1.3	0.49	0.61	0.27	0.17
Current Unearned Revenue	-	-	-	-	3.64	29.74
Other Current Liabilities	1.08	0.35	0.34	0.12	0.07	0.2
Total Current Liabilities	29.7	27.27	22.7	14.32	14.78	43.38
Long-Term Debt	-	-	-	-	-	10.89
Long-Term Leases	8.4	9.6	9.95	7.65	3.05	0.74
Long-Term Unearned Revenue	-	-	-	-	-	0.71
Total Liabilities	38.09	36.88	32.65	21.97	17.83	55.72
Common Stock	1,442	1,436	1,065	790.9	405.48	301.98
Additional Paid-In Capital	188.44	156.76	142.11	117.5	45.36	40.65
Retained Earnings	-833.79	-665.14	-482.75	-357.37	-278.49	-249.66
Comprehensive Income & Other	1.34	-0.08	-3	-0.99	-0.99	-0.99
Total Common Equity	797.81	927.92	721.5	550.03	171.36	91.98
Shareholders' Equity	797.81	927.92	721.5	550.03	171.36	91.98
Total Liabilities & Equity	835.9	964.8	754.15	572.01	189.19	147.7
Total Debt	9.79	10.9	10.44	8.26	3.32	16.45
Net Cash (Debt)	793.55	919.97	710.33	543.52	173.68	124.91
Net Cash Growth	26.35%	29.51%	30.69%	212.94%	39.05%	19.77%
Net Cash Per Share	10.47	13.75	11.73	12.46	4.82	4.28
Filing Date Shares Outstanding	76.24	75.43	63.04	52.94	36.83	35.97
Total Common Shares Outstanding	75.79	75.37	62.59	52.65	36.03	29.16
Working Capital	629.94	617.69	577.6	544.7	167	101.49
Book Value Per Share	10.53	12.31	11.53	10.45	4.76	3.15
Tangible Book Value	797.81	927.92	721.5	550.03	171.36	91.98
Tangible Book Value Per Share	10.53	12.31	11.53	10.45	4.76	3.15
Machinery	-	11.89	11	10.8	12.32	9.98
Leasehold Improvements	-	9.02	4.2	7.02	6.39	6.37

Source: S&P Capital IQ. Standard template. Financial Sources.